missing translation for 'onlineSavingsMsg'
Learn More

SB 431542, Tocris Bioscience™

Potent, selective inhibitor of TGF-βRI, ALK4 and ALK7

Brand:  Tocris Bioscience 1614/10

 View more versions of this product

Product Code. 18795776

  • 408.00 EUR / 10mg

[resources not loaded]

Explore more special offers
This item is not returnable. View return policy

Description

Description

SB 431542 is a potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor/ALK5 (IC50 = 94 nM), and its relatives ALK4 and ALK7. Suppresses TGF-β-induced proliferation of human osteosarcoma cells. Replaces SOX2 in reprogramming of fibroblasts into iPSCs. Stimulates proliferation, differentiation and sheet formation of ESC-derived endothelial cells. Inhibits TGF-β-induced EMT, migration, invasion and VEGF secretion in several human cancer cell lines.

SB 431542 synthesized to cGMP guidelines also available.

For more information about how SB 431542 may be used, see our protocols: 3D Culture of Lung Alveolar Cells, Differentiation of Hematopoietic Progenitors from hPSCs, Generating Midbrain Dopaminergic Neurons from hPSCs, Generating Vascular Organoids, Accelerated Induction of Cortical Neurons from hiPSCs .

Specifications

Specifications

SB 431542
4-4-2h-1,3-benzodioxol-5-yl-5-pyridin-2-yl-1h-imidazol-2-yl benzamide
C22H16N4O3
301836-41-9
10 mg
384.39
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Special Offers

Special Offers

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.